RhumbLine Advisers
ABEO icon

RhumbLine Advisers’s Abeona Therapeutics ABEO Stock Holding History

RhumbLine Advisers’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$250K Sell
55,847
-84
-0.2% -$420 ﹤0.01% 3009
2025
Q4 		$295K Sell
55,931
-7,742
-12% -$39K ﹤0.01% 2981
2025
Q3 		$336K Sell
63,673
-3,832
-6% -$24.3K ﹤0.01% 2918
2025
Q2 		$383K Buy
67,505
+65,651
+3,541% +$374K ﹤0.01% 2849
2025
Q1 		$8.82K Hold
1,854
– – ﹤0.01% 3849
2024
Q4 		$10.3K Hold
1,854
– – ﹤0.01% 3880
2024
Q3 		$11.7K Buy
1,854
+1,800
+3,333% +$9.4K ﹤0.01% 3871
2024
Q2 		$228 Sell
54
-4
-7% -$20 ﹤0.01% 4317
2024
Q1 		$420 Hold
58
– – ﹤0.01% 4195
2023
Q4 		$290 Hold
58
– – ﹤0.01% 4222
2023
Q3 		$243 Hold
58
– – ﹤0.01% 4262
2023
Q2 		$233 Buy
+58
New +$203 ﹤0.01% 4352
2021
Q2 		– Sell
-3,595
Closed -$169K – 2981
2021
Q1 		$169K Hold
3,595
– – ﹤0.01% 2866
2020
Q4 		$141K Buy
3,595
+612
+21% +$20.8K ﹤0.01% 2910
2020
Q3 		$76K Sell
2,983
-573
-16% -$36.1K ﹤0.01% 2914
2020
Q2 		$259K Buy
3,556
+705
+25% +$48.7K ﹤0.01% 2644
2020
Q1 		$150K Buy
2,851
+750
+36% +$50.1K ﹤0.01% 2674
2019
Q4 		$172K Buy
2,101
+67
+3% +$4.73K ﹤0.01% 2786
2019
Q3 		$115K Buy
2,034
+168
+9% +$12.6K ﹤0.01% 2862
2019
Q2 		$223K Buy
1,866
+243
+15% +$40.7K ﹤0.01% 2745
2019
Q1 		$299K Sell
1,623
-43
-3% -$7.69K ﹤0.01% 2555
2018
Q4 		$297K Buy
1,666
+532
+47% +$116K ﹤0.01% 2548
2018
Q3 		$363K Sell
1,134
-56
-5% -$19.9K ﹤0.01% 2419
2018
Q2 		$476K Buy
1,190
+70
+6% +$30.6K ﹤0.01% 2326
2018
Q1 		$402K Buy
1,120
+53
+5% +$19.7K ﹤0.01% 2298
2017
Q4 		$423K Sell
1,067
-119
-10% -$49.2K ﹤0.01% 2304
2017
Q3 		$505K Buy
1,186
+1
+0.1% +$269 ﹤0.01% 2301
2017
Q2 		$190K Buy
+1,185
New +$162K ﹤0.01% 2778
2016
Q2 		– Sell
-491
Closed -$31K – 2983
2016
Q1 		$31K Hold
491
– – ﹤0.01% 2976
2015
Q4 		$41K Buy
+491
New +$49.2K ﹤0.01% 3008

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RhumbLine Advisers's ABEO Position: Q1 2026 in Review

RhumbLine Advisers reduced its Abeona Therapeutics (ABEO) stake by 0.15% in Q1 2026, selling an estimated $420 and leaving 55,847 shares worth $250K. The position accounts for ﹤0.01% of the portfolio, ranked #3009.

RhumbLine Advisers first reported a position in ABEO in Q4 2015 and has held it in 30 quarters since. The position peaked at $505K in Q3 2017. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • RhumbLine Advisers held 55,847 shares of Abeona Therapeutics worth $250K as of Q1 2026.
  • RhumbLine Advisers sold 84 Abeona Therapeutics shares in Q1 2026, an estimated $420.
  • Abeona Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3009 holding.
  • RhumbLine Advisers first reported a position in Abeona Therapeutics in Q4 2015 and has held it in 30 quarters since.
  • RhumbLine Advisers's Abeona Therapeutics position peaked at $505K in Q3 2017.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.